New brucella antigens, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits
CA 2263791 A1 · Owner: Innogenetics N.V. · Inventors: Dubray, Gerard; Tibor, Anne; Verger, Jean-Michel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to isolated and pure Brucella antigens to , nucleic acids encoding said antigens as well as to diagnostic methods and , kits using said antigens and nucleic acids for detecting Brucella infection in human and cattle. The invention also relates to recombinant polypeptides a , process for preparing the same and their use in methods and kits for the diagnosis of Brucella infection. The invention also relates to the use of said isolated antigens, or said recombinant polypeptides or said nucleic acids as , an active principle of a vaccine composition against Brucella infection. The invention relates also to a vaccine composition comprising a recombinant …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 27, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 27, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 27, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.